局部进展期食管鳞癌新辅助治疗模式研究进展  

Progress of neoadjuvant therapy for locally advanced esophageal squamous cell cancer

作　　者：朱多杰 李玉民 ZHU Duojie;LI Yumin(Department of Thoracic Surgery,Lanzhou University Second Hospital,Gansu Lanzhou 730000,China;Gansu Provincial Key Laboratory of Digestive System Oncology,Gansu Lanzhou 730030,China)

机构地区：[1]兰州大学第二医院胸外科,甘肃兰州730000 [2]甘肃省消化系统肿瘤重点实验室,甘肃兰州730030

出　　处：《现代肿瘤医学》2024年第1期159-163,共5页Journal of Modern Oncology

基　　金：2021年陇原青年创新创业人才(团队)项目(编号:2021LQTD11)。

摘　　要：食管癌是全球常见的恶性肿瘤之一,其中包括中国、日本、韩国在内的东亚地区中,食管鳞状细胞癌(esophageal squamous cell cancer,ESCC)占食管癌的90%以上。目前局部进展期食管鳞癌的主要治疗手段为新辅助治疗联合外科手术切除。然而即使按照标准治疗指南进行治疗,局部进展期食管鳞癌患者的总体生存率仍不令人满意。未来寄希望于通过新辅助放化疗、化疗或新兴的免疫治疗相关研究的持续探索,进一步改善食管鳞癌患者总生存期。在此,我们回顾和总结了局部进展期食管鳞癌不同术前新辅助治疗模式的疗效的当前证据。Esophageal squamous cell carcinoma(ESCC) is one of the most common malignancies worldwide,especially in East Asia.ESCC accounts for more than 90% of esophageal cancer.Currently,esophagectomy following neoadjuvant therapy is the mainstay of treatment for locally advanced ESCC.However,the overall survival rate of patients with locally advanced ESCC is not satisfactory even when treated following the standard treatment guidelines.With neoadjuvant chemoradiotherapy,chemotherapy,or emerging immunotherapy,continuous exploration of efficacy in relation to ESCC is expected to improve overall survival further.Here,we reviewed and summarized current progress of neoadjuvant therapy for locally advanced ESCC.

关 键 词：食管鳞状细胞癌 局部进展期 新辅助放化疗 新辅助化疗 新辅助免疫治疗 

分 类 号：R735.1[医药卫生—肿瘤]